Neurological Complications After Transcatheter Aortic Valve Replacement: A Review
- PMID: 39136954
- DOI: 10.1213/ANE.0000000000007087
Neurological Complications After Transcatheter Aortic Valve Replacement: A Review
Abstract
Transcatheter aortic valve replacement (TAVR) has become the dominant procedural modality for aortic valve replacement in the United States. The reported rates of neurological complications in patients undergoing TAVR have changed over time and are dependent on diagnostic definitions and modalities. Most strokes after TAVR are likely embolic in origin, and the incidence of stroke has decreased over time. Studies have yielded conflicting results when comparing stroke rates between TAVR and surgical aortic valve replacement (SAVR), especially due to differences in diagnostic criteria and neurocognitive testing. In this narrative review, we summarize the available data on the incidence of stroke, delirium, and cognitive decline after TAVR and highlight potential areas in need of future research. We also discuss silent cerebral ischemic lesions (SCILs) and their association with a decline in postoperative neurocognitive status after TAVR. Finally, we describe that the risk of delirium and postoperative decline is increased when nonfemoral access routes are used, and we highlight the need for standardized imaging and valid, repeatable methodologies to assess cognitive changes after TAVR.
Copyright © 2024 International Anesthesia Research Society.
Conflict of interest statement
Conflicts of Interest, Funding: See DISCLOSURES at the the end of this article.
References
-
- Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:2492–2516.
-
- Virgili G, Romano SM, Valenti R, et al. Transcatheter aortic valve implantation in younger patients: a new challenge. Medicina (Kaunas). 2021;57:883.
-
- Mack MJ, Leon MB, Thourani VH, et al.; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705.
-
- Markham R, Sharma R. A review of the PARTNER trials. Interv Cardiol Clin. 2020;9:461–467.
-
- Popma JJ, Deeb GM, Yakubov SJ, et al.; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–1715.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources